Aktuellt
SENASTE
Redeye provides its initial comments on the Q1 2024 report from Scandinavian Chemotech, which was broadly above our expectations. Sales came in at SEK1.3m, better than our estimated SEK0.8m. The company manifested solid cost control in the quarter, leading to a lower-than-anticipated loss at the EBIT level. We will raise our valuation slightly as we reduce cost estimates for the remainder of the year.
LÄS MER
